Literature DB >> 15847664

Automated preparation of platelet concentrates from pooled buffy coats: in vitro studies and experiences with the OrbiSac system.

S Larsson1, P Sandgren, A Sjödin, M Vesterinen, H Gulliksson.   

Abstract

BACKGROUND: The aim was to evaluate platelet concentrates (PCs) prepared by the automated OrbiSac system, from pooled buffy coats (BCs) stored in a platelet (PLT) additive solution. STUDY DESIGN AND METHODS: Experiment 1 was a paired in vitro study of PCs (from six BCs), prepared by automated and manual procedures. Experiments 2 and 3 evaluated PCs from OrbiSac (from six BCs); Experiment 3 included selection of BCs based on donor data. Experiment 4 was a paired in vitro study of PCs (from six BCs) with an integrated white blood cell (WBC) filter and two different storage containers. Experiment 5 evaluated PCs (from six BCs) from the OrbiSac with an integrated WBC filter. Experiment 6 was similar to Experiment 5 with computer-selected pools of 5 BCs. The in vitro studies evaluated the effects of 7-day storage of PLTs regarding PLT metabolism and disintegration.
RESULTS: Experiments 1 and 4 had similar in vitro results. In Experiment 2, PLT content was 370 x 10(9) +/- 70 x 10(9) per PC and recovery from BCs was 76 +/- 6 percent. In Experiment 3, the PLT content was 380 x 10(9) +/- 50 x 10(9) per PC and variation was reduced compared with randomly pooled BCs. In Experiment 5, increased PLT content was found (420 x 10(9) +/- 70 x 10(9) per PC and recovery from BCs of 80 +/- 5%). In Experiment 6, five rather than six BCs gave 340 x 10(9) +/- 60 x 10(9) PLTs per PC and recovery was 79 +/- 5 percent.
CONCLUSION: These in vitro studies suggest that the OrbiSac technique is equivalent to the standard manual method regarding the PLT in vitro characteristics during storage for 7 days. The results of standardizing the PLT count in PCs by selecting the BCs pools on the basis of the blood donor PLT concentration were encouraging.

Entities:  

Mesh:

Year:  2005        PMID: 15847664     DOI: 10.1111/j.1537-2995.2005.04096.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system.

Authors:  Eva María Plaza; María Luisa Lozano; Isabel Sánchez Guiu; José Manuel Egea; Vicente Vicente; Laura Collantes De Terán; José Rivera
Journal:  Blood Transfus       Date:  2012-04-13       Impact factor: 3.443

2.  Storage of buffy-coat-derived platelets in additive solution: in vitro effects on platelets of the air bubbles and foam included in the final unit.

Authors:  Per Sandgren; Kharija Saeed
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

3.  Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation.

Authors:  Pilar Solves; Nelly Carpio; Aitana Balaguer; Samuel Romero; Gloria Iacoboni; Inés Gómez; Ignacio Lorenzo; Federico Moscardó; Jaime Sanz; Francisca Lopez; Guillermo Martin; Isidro Jarque; Pau Montesinos; Javier De La Rubia; Guillermo Sanz; Miguel A Sanz
Journal:  Blood Transfus       Date:  2015-02-02       Impact factor: 3.443

4.  The effects of pneumatic tube transport on fresh and stored platelets in additive solution.

Authors:  Per Sandgren; Stella Larsson; Poon Wai-San; Beatrice Aspevall-Diedrich
Journal:  Blood Transfus       Date:  2013-12-03       Impact factor: 3.443

Review 5.  Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study.

Authors:  Ana Villalba; Marta Santiago; Carmen Freiria; Pau Montesinos; Ines Gomez; Carolina Fuentes; Rebeca Rodriguez-Veiga; José María Fernandez; Guillermo Sanz; Miguel Angel Sanz; Nelly Carpio; Pilar Solves
Journal:  Transfus Med Hemother       Date:  2018-05-03       Impact factor: 3.747

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.